FI3980411T3 - N-(5-(6-etoksipyratsin-2-yyli)pyridin-2-yyli)-4-(2-(etyylisulfonamido)pyrimidin-4-yyli)tetrahydro-2h-pyran-4-karboksamidi ihmisen ctps1:n estäjänä proliferatiivisten sairauksien hoitoon - Google Patents

N-(5-(6-etoksipyratsin-2-yyli)pyridin-2-yyli)-4-(2-(etyylisulfonamido)pyrimidin-4-yyli)tetrahydro-2h-pyran-4-karboksamidi ihmisen ctps1:n estäjänä proliferatiivisten sairauksien hoitoon

Info

Publication number
FI3980411T3
FI3980411T3 FIEP20749934.4T FI20749934T FI3980411T3 FI 3980411 T3 FI3980411 T3 FI 3980411T3 FI 20749934 T FI20749934 T FI 20749934T FI 3980411 T3 FI3980411 T3 FI 3980411T3
Authority
FI
Finland
Prior art keywords
solvate
compound
lymphoma
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
FIEP20749934.4T
Other languages
English (en)
Finnish (fi)
Inventor
Abdul Quddus
Andrew Novak
David Cousin
Emma Blackham
Geraint Jones
Joseph Wrigglesworth
Lorna Duffy
Louise Birch
Pascal George
Saleh Ahmed
Original Assignee
Step Pharma S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Step Pharma S A S filed Critical Step Pharma S A S
Application granted granted Critical
Publication of FI3980411T3 publication Critical patent/FI3980411T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C07D239/40—One sulfur atom as doubly bound sulfur atom or as unsubstituted mercapto radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
FIEP20749934.4T 2019-06-04 2020-06-04 N-(5-(6-etoksipyratsin-2-yyli)pyridin-2-yyli)-4-(2-(etyylisulfonamido)pyrimidin-4-yyli)tetrahydro-2h-pyran-4-karboksamidi ihmisen ctps1:n estäjänä proliferatiivisten sairauksien hoitoon FI3980411T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19305713 2019-06-04
EP19306144 2019-09-20
PCT/IB2020/000559 WO2020245664A1 (en) 2019-06-04 2020-06-04 N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(methylsulfonamido)pyrimidin-4-yl) tetrahydro-2h-pyran-4-carboxamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
FI3980411T3 true FI3980411T3 (fi) 2025-10-28

Family

ID=71895028

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP20749934.4T FI3980411T3 (fi) 2019-06-04 2020-06-04 N-(5-(6-etoksipyratsin-2-yyli)pyridin-2-yyli)-4-(2-(etyylisulfonamido)pyrimidin-4-yyli)tetrahydro-2h-pyran-4-karboksamidi ihmisen ctps1:n estäjänä proliferatiivisten sairauksien hoitoon

Country Status (10)

Country Link
US (2) US12466810B2 (cg-RX-API-DMAC7.html)
EP (1) EP3980411B1 (cg-RX-API-DMAC7.html)
JP (1) JP7595593B2 (cg-RX-API-DMAC7.html)
CN (1) CN114008039B (cg-RX-API-DMAC7.html)
DK (1) DK3980411T3 (cg-RX-API-DMAC7.html)
ES (1) ES3044436T3 (cg-RX-API-DMAC7.html)
FI (1) FI3980411T3 (cg-RX-API-DMAC7.html)
HU (1) HUE073329T2 (cg-RX-API-DMAC7.html)
IL (1) IL288508B2 (cg-RX-API-DMAC7.html)
WO (1) WO2020245664A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019106146A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
EP3717459B1 (en) 2017-11-30 2026-01-21 Step Pharma S.A.S. Compounds
EP4232425A4 (en) * 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
WO2022165404A1 (en) * 2021-02-01 2022-08-04 University Of Southern California Enzyme inhibitors and viral infection therapy
WO2023166077A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination of a ctps1 inhibitor and a atr inhibitor in cancer therapy
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor
CA3244038A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. COMBINATION OF CTPS1 AND BCL-2 INHIBITORS FOR CANCER TREATMENT
WO2023166078A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor
WO2024133730A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
WO2024133721A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer
CN118359588A (zh) * 2023-01-19 2024-07-19 杭州英创医药科技有限公司 作为ctps1抑制剂的化合物
WO2026027753A1 (en) * 2024-08-02 2026-02-05 Step Pharma S.A.S. Ctps1 inhibitors for the treatment of myeloproliferative neoplasms

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ523882A (en) 2000-08-21 2004-11-26 Pacific Corp Novel thiourea derivatives and the pharmaceutical compositions containing the same
US7091201B2 (en) 2000-09-25 2006-08-15 Actelion Pharmaceuticals Ltd. Arylalkane-sulfonamides having endothelin-antagonist activity
US20030158218A1 (en) 2001-12-21 2003-08-21 Nantermet Philippe G. Thrombin inhibitors
ES2325836T3 (es) 2004-07-26 2009-09-21 Merck Serono Sa Derivados de la n.hidroxiamida y uso de los mismos.
EP1659113A1 (en) 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
JP2011506445A (ja) 2007-12-13 2011-03-03 アムジエン・インコーポレーテツド γ−セクレターゼ調節剤
AU2009284098B2 (en) * 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
KR101097312B1 (ko) 2009-08-10 2011-12-23 삼성모바일디스플레이주식회사 유기 발광 소자
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
JP5938038B2 (ja) * 2010-08-03 2016-06-22 ネルヴィアーノ・メディカル・サイエンシズ・ソチエタ・ア・レスポンサビリタ・リミタータ ピラゾロフェニル−ベンゼンスルホンアミド化合物の誘導体及びその抗腫瘍薬としての使用
WO2012068343A1 (en) * 2010-11-17 2012-05-24 Amgen Inc. Quinoline derivatives as pik3 inhibitors
EP2651930B1 (en) 2010-12-16 2015-10-28 Boehringer Ingelheim International GmbH Biarylamide inhibitors of leukotriene production
JP2016028795A (ja) 2013-03-28 2016-03-03 国立研究開発法人科学技術振興機構 触媒金属ナノ粒子含有複合体及びその利用
JP2016523818A (ja) 2013-04-18 2016-08-12 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル それを必要とする被験体におけるt細胞増殖を阻害するための方法及び医薬組成物(ctps1阻害剤、例えばノルロイシン)
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
GB201322333D0 (en) 2013-12-17 2014-01-29 Agency Science Tech & Res WNT pathway modulators
SMT201900615T1 (it) 2014-10-08 2020-01-14 Redx Pharma Plc Derivati di acetammide n-piridinile come inibitori del percorso di segnalazione wnt
CN104262071A (zh) 2014-10-16 2015-01-07 中国科学院山西煤炭化学研究所 一种联苯类化合物的光催化合成方法
EP3492454A1 (en) * 2017-11-30 2019-06-05 Step Pharma S.A.S. Compounds
WO2019106146A1 (en) 2017-11-30 2019-06-06 Step Pharma S.A.S. Compounds
EP3717459B1 (en) 2017-11-30 2026-01-21 Step Pharma S.A.S. Compounds
AU2018413791B2 (en) 2018-03-23 2023-05-18 Step Pharma S.A.S. Aminopyrimidine derivatives as CTPS1 inhibitors
US20230192673A1 (en) 2018-06-04 2023-06-22 Step Pharma S.A.S. Compounds
PL3870574T3 (pl) 2018-10-23 2023-05-02 Step Pharma S.A.S. Pochodne aminopirymidyny/pirazyny jako inhibitory CTPS1
WO2020245665A1 (en) 2019-06-04 2020-12-10 Step Pharma S.A.S. N-(4-(5-chloropyridin-3-yl)phenyl)-2-(2-(cyclopropanesulfonamido)pyrimidin-4-yl) butanamide derivatives and related compounds as human ctps1 inhibitors for the treatment of proliferative diseases
US20230020663A1 (en) 2019-09-20 2023-01-19 Step Pharma S.A.S. Sulfonamide inhibitors as ctps1 inhibitors
WO2021053402A2 (en) 2019-09-20 2021-03-25 Step Pharma S.A.S. Compounds
EP4232425A4 (en) 2020-10-23 2024-07-24 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
WO2023166080A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor
CA3244038A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. COMBINATION OF CTPS1 AND BCL-2 INHIBITORS FOR CANCER TREATMENT
WO2023166077A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination of a ctps1 inhibitor and a atr inhibitor in cancer therapy
WO2023166078A1 (en) 2022-03-01 2023-09-07 Step Pharma S.A.S. Combination treatments comprising a ctps1 inhibitor and a chek1 inhibitor
US20250270200A1 (en) 2022-04-21 2025-08-28 Nimbus Clotho, Inc. Ctps1 inhibitors and uses thereof
WO2024133721A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer
WO2024133730A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Ctps1 inhibitors for use in the treatment of ctps2 deficient cancer
CN118359588A (zh) 2023-01-19 2024-07-19 杭州英创医药科技有限公司 作为ctps1抑制剂的化合物

Also Published As

Publication number Publication date
CN114008039A (zh) 2022-02-01
WO2020245664A1 (en) 2020-12-10
HUE073329T2 (hu) 2026-01-28
US20220324837A1 (en) 2022-10-13
JP7595593B2 (ja) 2024-12-06
CN114008039B (zh) 2024-01-16
EP3980411B1 (en) 2025-07-23
US20260159502A1 (en) 2026-06-11
US12466810B2 (en) 2025-11-11
JP2022536092A (ja) 2022-08-12
DK3980411T3 (da) 2025-10-13
ES3044436T3 (en) 2025-11-26
IL288508A (en) 2022-01-01
IL288508B2 (en) 2026-02-01
EP3980411A1 (en) 2022-04-13
IL288508B1 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
HRP20230328T1 (hr) Derivati aminopirimidina/pirazina kao inhibitori ctps1
IL277455B2 (en) Aminopyrimidine derivatives as ctps1 inhibitors
IL275129B1 (en) New spirobicyclic analogs
EA201270013A1 (ru) Гетероциклические соединения и их применение
WO2008009076A3 (en) Substituted pyrido(3,2-d)pyrimidines and pharmaceutical compositions for treating viral infections
JP2018528946A5 (cg-RX-API-DMAC7.html)
ECSP034809A (es) Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc
CR20210271A (es) Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso
WO2011123751A3 (en) Heterocyclic compounds and their use as pi3k inhibitors
SV2005002148A (es) "compuestos moduladores de la actividad c-kit y usos de los mismos"
CA2680853A1 (en) 3- substituted quinoline or quinoxaline derivatives and their use as phosphatidylinositol 3-kinase (pi3k) inhibitors
EA200901276A1 (ru) Гетероциклические соединения и их применение
RU2014153591A (ru) Новые соединения
EP4212532A3 (en) Mitragynine analogs and uses thereof
MX2011013901A (es) Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.
CL2020002350A1 (es) Formulación farmacéutica novedosa que comprende antagonistas del receptor dual nk-1/nk-3
US9226859B1 (en) Pet diaper and clothing component system
ES2337596T3 (es) Antagonistas del receptor de glucacion, preparacion y usos terapeuticaos.
DOP2005000038A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5"
MX2012015147A (es) Compuestos heterociclicos y su uso como inhibidores de la actividad pi3k.
WO2007116396A1 (en) Treatment of hematological malignancies with fts and a bcr-abl tyrosine kinase inhibitor
Werdehausen et al. Lipophilicity but not stereospecificity is a major determinant of local anaesthetic-induced cytotoxicity in human T-lymphoma cells
PE20061318A1 (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos
MX2021015319A (es) Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos.
KR20210021993A (ko) 흡수성 물품